| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The molecular target is not a single receptor; 5-ALA is taken up by cells and converted in the heme pathway to protoporphyrin IX (PpIX), which accumulates in mitochondria and acts as a photosensitizer upon light activation, generating reactive oxygen species that induce tumor cell death. It also modulates heme biosynthesis and may affect mitochondrial function and oxidative stress pathways.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, 5-aminolevulinic acid-d2 HCl is taken up by tumor cells and converted to PpIX, which accumulates intracellularly and produces cytotoxicity upon light irradiation; the deuterated form retains PpIX synthesis and photodynamic activity while enabling LC-MS/MS quantification of 5-ALA and its metabolites in cells and tissues. |
| ln Vivo |
In vivo, oral or topical 5-aminolevulinic acid-d2 HCl produces tumor-selective PpIX accumulation and enables fluorescence-guided resection and photodynamic therapy of gliomas, skin cancers, and other tumors; it is well tolerated and the labeled form is used to quantify tissue concentrations and PpIX formation in pharmacokinetic and pharmacodynamic studies.
|
| Enzyme Assay |
Noncellular assays measure 5-aminolevulinic acid-d2 conversion to PpIX in cell-free heme biosynthesis systems or tissue homogenates by fluorescence spectroscopy; porphobilinogen deaminase and ferrochelatase activities are measured with deuterated substrates, and PpIX phototoxicity is assessed by irradiating solutions and measuring reactive oxygen species.
|
| Cell Assay |
Cellular assays use glioma or skin cancer cell lines treated with 5-aminolevulinic acid-d2 HCl; PpIX fluorescence is measured by flow cytometry or microscopy, photodynamic cytotoxicity by MTT or clonogenic assays after light irradiation, and heme pathway enzyme expression by immunoblotting, with LC-MS/MS confirming 5-ALA uptake.
|
| Animal Protocol |
Animal protocols administer 5-aminolevulinic acid-d2 HCl orally or topically to mice bearing glioma or skin tumor xenografts; PpIX fluorescence in tumor and normal tissue is measured by spectroscopy or imaging, photodynamic therapy efficacy is assessed by tumor growth and survival, and plasma and tissue concentrations are quantified by LC-MS/MS.
|
| References |
|
| Molecular Formula |
C5H10CLNO3
|
|---|---|
| Molecular Weight |
167.590800762177
|
| Exact Mass |
169.047
|
| CAS # |
187237-35-0
|
| Related CAS # |
5-Aminolevulinic acid hydrochloride;5451-09-2
|
| PubChem CID |
88279086
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
0.881
|
| tPSA |
80.39
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
121
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(CC(=O)CN)C(=O)O.Cl
|
| InChi Key |
ZLHFONARZHCSET-IYPYQTRPSA-N
|
| InChi Code |
InChI=1S/C5H9NO3.ClH/c6-3-4(7)1-2-5(8)9;/h1-3,6H2,(H,8,9);1H/i2D2;
|
| Chemical Name |
5-amino-2,2-dideuterio-4-oxopentanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~12.5 mg/mL (~73.7 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9669 mL | 29.8347 mL | 59.6694 mL | |
| 5 mM | 1.1934 mL | 5.9669 mL | 11.9339 mL | |
| 10 mM | 0.5967 mL | 2.9835 mL | 5.9669 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.